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Abstract. The F-actin binding and cross-linking proper- 
ties of skeletal muscle dystrophin-glycoprotein complex 
were examined using high and low speed cosedimenta- 
tion assays, microcapillary falling ball viscometry, and 
electron microscopy. Dystrophin-glycoprotein complex 
binding to F-actin saturated near 0.042 _+ 0.005 tool/ 
mol, which corresponds to one dystrophin per 24 actin 
monomers. Dystrophin-glycoprotein complex bound to 
F-actin with an average apparent Ka for dystrophin of 
0.5 txM. These results demonstrate that native, full- 
length dystrophin in the glycoprotein complex binds 
F-actin with some properties similar to those measured 
for several members of the actin cross-linking super- 
family of proteins. However, we failed to observe dys- 
trophin-glycoprotein complex-induced cross-linking of 
F-actin by three different methods, each positively con- 
trolled with et-actinin.  Furthermore, high speed cosedi- 
mentation analysis of dystrophin-glycoprotein complex 
digested with calpain revealed a novel F-actin binding 
site located near the middle of the dystrophin rod do- 
main. Recombinant dystrophin fragments correspond- 
ing to the novel actin binding site and the first 246 
amino acids of dystrophin both bound F-actin but with 
significantly lower affinity and higher capacity than was 
observed with purified dystrophin-glycoprotein com- 
plex. Finally, dystrophin-glycoprotein complex was ob- 
served to significantly slow the depolymerization of 
F-actin, suggesting that dystrophin may lie along side 
an actin filament through interaction with multiple ac- 
tin monomers. These data suggest that although dystro- 
phin is most closely related to the actin cross-linking su- 
perfamily based on sequence homology, dystrophin 
binds F-actin in a manner more analogous to actin side- 
binding proteins. 
T 
HE gene defective in Duchenne muscular dystrophy 
encodes a  number  of alternatively  promoted  and 
spliced transcripts which give rise to several struc- 
turally distinct proteins collectively referred to as dystro- 
phins (Ahn and Kunkel, 1993). Striated muscle dystrophin 
is predominantly expressed as a 427 kD, four domain pro- 
tein with the first three domains exhibiting significant  se- 
quence homology with the cytoskeletal proteins et-actinin 
and  spectrin  (Koenig et al.,  1988; Matsudaira,  1991): an 
amino-terminal, putative actin-binding domain; a rod-like 
domain comprised of 24 triple helical coiled coil repeats; 
a  cysteine-rich  domain  and  a  carboxy-terminal  domain. 
Skeletal muscle dystrophin has been isolated as part of a 
large, tightly associated oligomeric complex of sarcolem- 
mal  proteins  commonly referred  to as  the dystrophin- 
glycoprotein complex (Ervasti et al.,  1990; Yoshida and 
Ozawa, 1990; Ervasti and Campbell,  1991). Integral  and 
peripheral  membrane  components  of  the  glycoprotein 
complex bind to the cysteine-rich and/or carboxy-terminal 
domains of dystrophin (Suzuki et al., 1992; Kramarcy et al., 
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1994; Suzuki et al.,  1994),  ultimately linking dystrophin 
to a highly  glycosylated, extracellular component named 
et-dystroglycan  (Ibraghimov-Beskrovnaya  et  al.,  1992). 
a-Dystroglycan in turn binds to the laminin  family of pro- 
teins  (Ibraghimov-Beskrovnaya et al.,  1992; Ervasti  and 
Campbell,  1993a; Sunada  et al.,  1994; Pall  et  al.,  1996). 
Many studies have demonstrated that both intact dystro- 
phin (Ervasti and Campbell, 1993a; Fabbrizio et al., 1993; 
Senter et al.,  1993; Lebart et al.,  1995) and recombinant 
proteins corresponding to its amino-terminal  domain (Hem- 
mings et al., 1992; Way et al., 1992; Fabbrizio et al., 1993; 
Corrado et al., 1994; Jarrett and Foster, 1995) are capable 
of binding F-actin. These data support a model for the dys- 
trophin-glycoprotein  complex in linking  the  actin-based, 
cortical cytoskeleton with the extracellular matrix (Ervasti 
and Campbell, 1993b). The importance of the dystrophin- 
glycoprotein complex is  evident  from  numerous  studies 
demonstrating that the loss of or deletions within dystro- 
phin, components of the glycoprotein complex or laminin-2, 
can  all  lead to forms of muscular dystrophy (Campbell, 
1995; Worton,  1995). However, the  exact cellular  func- 
tion(s) of the dystrophin-glycoprotein complex remains to 
be elucidated. 
The transmembrane linkage formed by the dystrophin- 
glycoprotein complex may play a structural role in main- 
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tion  (Menke  and Jockusch,  1991; Stedman  et  al.,  1991; 
Petrof et al.,  1993; Pasternak et al.,  1995). As an alterna- 
tive, or perhaps additional function, the dystrophin-glyco- 
protein complex may further serve to organize or modu- 
late other proteins involved in signal transduction (Sealock 
and Froehner,  1994; Yang  et  al.,  1995; Brenman  et  al., 
1996). Regarding a structural function, it is not clear whether 
or how the linear association of proteins comprising the 
dystrophin-glycoprotein complex  may  be  further  orga- 
nized into higher ordered networks. Since full-length dys- 
trophin is most closely related to the actin cross-linking su- 
perfamily of proteins based on sequence homology (Koenig 
et al., 1988; Matsudaira, 1991), it has been speculated that 
dystrophin may form antiparallel dimers  that cross-link 
different actin filaments, ultimately forming a  hexagonal 
lattice (Koenig and Kunkel, 1990; Ahn and Kunkel, 1993). 
Alternatively, there  may  exist  additional  actin  binding 
sites within dystrophin yielding a bivalent monomer that 
cross-links actin filaments in a manner similar to fimbrin 
(Matsudaira, 1991). However, neither of these possibilities 
has been examined experimentally. 
To address these issues, we have quantitatively charac- 
terized the F-actin binding properties of purified dystro- 
phin-glycoprotein complex and show that purified skeletal 
muscle  dystrophin-glycoprotein  complex  binds  F-actin 
with some biochemical properties similar to several other 
native  members  of  the  actin  cross-linking  superfamily. 
However, in contrast with the other members of the F-actin 
cross-linking superfamily of proteins,  dystrophin in  the 
glycoprotein complex does not appear to cross-link F-actin. 
Furthermore, we present evidence for a novel actin bind- 
ing site located near the middle of the dystrophin rod do- 
main. Finally, we observed that dystrophin-glycoprotein 
complex significantly slows depolymerization of F-actin. 
Taken together, our results suggest that dystrophin may 
bind along side an actin filament with 0.5 I~M affinity via 
multiple lower affinity binding sites distributed through- 
out its amino-terminal and rod domains. 
Materials and Methods 
Purification of Dystrophin--Glycoprotein Complex 
Dystrophin-glycoprotein complex was prepared from KCl-washed rabbit 
skeletal muscle membranes as previously described (Ervasti et al., 1991) 
with slight modifications. In brief, the digitonin solubilate obtained from 1 g 
of KCl-washed membranes was circulated overnight on a 60-ml succiny- 
lated WGA-agarose column (Vector Laboratories, Burlingame, CA) at 
4°C. The succinylated WGA-agarose column was washed with 224 ml of 
buffer A (0.1% digitonin, 50 mM Tris-HC1, pH 7.4, 0.75 mM benzamidine, 
0.1 mM PMSF) containing 0.5 M  NaCI, followed by 224 ml of buffer A, 
pH 7.8, and finally eluted with 224 ml of buffer A, pH 8.0, containing 0.3 M 
N-acetylglucosamine. The N-acetylglucosamine eluate was adjusted to pH 
7.4 with HCI  and applied to a  3-ml DEAE-cellulose (Whatman DE52) 
column. The column was step-eluted with buffer A containing the follow- 
ing NaCI gradient profile: 0 M  (20 ml), 0.08 M  (20 ml), 0.08-0.11 M (4 
ml), 0.11 M (20 ml), 0.11-0.18 M (4 ml), 0.18 M (20 ml), 0.18--1 M (4 ml), 1 M 
(28 ml). The dystrophin-glycoprotein complex eluted with 0.18 M  NaCI 
was concentrated to 2.5 ml in a Centriplus 100 (Amicon, Beverly, MA), 
loaded onto a  PD-10 column (Pharmacia Biotech, Piscataway, NJ),  and 
eluted with 3.5 ml of actin binding buffer (10 mM Tris-HCl, pH 8.0, 1 rnM 
NAN3, 0.1  mM ATP, 0.1  M  NaCI, 2  mM MgCI~, 0.2 mM dithiothreitol 
0.1%  digitonin,  1  mM EGTA).  Dystrophin-glycoprotein complex was 
also prepared from KCl-washed rabbit skeletal muscle membranes solubi- 
lized with 1% Triton X-100 in the presence of 0.15 M  NaCI. Chromato- 
graphic procedures were performed as described above except that all 
buffers contained 0.1% Triton X-100 instead of 0.1%  digitonin and the 
succinylated WGA-agarose column was washed with 224 ml of buffer A 
containing 0.15 M NaCI instead of 0.5 M NaCI. Purified dystrophin-glyco- 
protein complex was concentrated to 0.2--0.3 ml in a Centricon 100 (Ami- 
con) and assayed for protein with the Bio-Rad DC Protein Assay kit using 
BSA as standard. The dystrophin concentrations referred to in the text 
and figure legends were based on the measured dystrophin-glycoprotein 
complex protein concentration, the observation that dystrophin comprises 
50% of the Coomassie Blue-stained protein in electrophoretically sepa- 
rated dystrophin-glycoprotein complex (Yoshida and Ozawa,  1990;  Er- 
vasti and Campbell, 1991)  and the predicted molecular weight of dystro- 
phin as 427,000 (Koenig et al., 1988). 
Purification of  Actin 
Actin was purified from rabbit skeletal muscle using the method of Pardee 
and Spudich (1982) and further purified by gel filtration on a Sephacryl 
S-200 column (Pharmacia Biotech) according to MacLean-Fletcher and Pol- 
lard (1980a).  Gel filtered G-actin was either concentrated from 15 ml to 
~0.5 ml in a Centricon 10 (Amicon) or polymerized to F-actin and concen- 
trated by sedimentation at 100,000 g  and resuspended in 0.5-1.0 ml of 2 
mM Tris-HCl, pH 8.0,  1 mM NaN  3, 0.1 mM ATP, 0.2 mM CaClz, 50 mM 
KC1, 2 mM MgCI  2. Actin concentration was determined by absorbance us- 
ing E29  o = 0.65 cm2/mg (MacLean-Fletcher and Pollard, 1980a). 
High Speed Sedimentation Assay 
Various amounts of purified  dystrophin-glycoprotein complex in  actin 
binding buffer were mixed with concentrated F-actin in a total volume of 
60 p~l and incubated for 30 min at room temperature. The samples were 
subjected to centrifugation at 100,000 g for 20 min, supernatants carefully 
decanted  and  the pellets  redissolved in an  equivalent volume of actin 
binding buffer. To quantify the amount of dystrophin-glycoprotein com- 
plex bound to F-actin, equal volumes of the supernatants and resuspended 
pellets were separated electrophoretically on 3-12% SDS-polyacrylamide 
gels (Ervasti and Campbell, 1993a). Coomassie blue-stained gels were an- 
alyzed densitometrically using a  Bio-Rad Model GS-670 Imaging Densi- 
tometer. The intensities of the scanned bands were quantitated by volume 
integration after background subtraction. Binding data were analyzed by 
nonlinear regression analysis with the computer program Kinetics (Brooks, 
1992). Dystrophin-glycoprotein complex binding to F-actin was also mea- 
sured in the presence of 5 p~M bovine brain calmodulin (Calbiochem No- 
vabiochem, San Diego, CA), or wheat germ calmodulin (the kind gift of 
Dr. Gale Strasburg) in actin binding buffer or in actin binding buffer con- 
taining 0.2 mM CaCl2 instead of EGTA. 
Low Speed Sedimentation Assay 
Chicken gizzard c~-actinin (Sigma) or dystrophin-glycoprotein complex in 
10 mM Tris-HCl, pH 8.0, I mM NaN  3, 0.1 mM ATP, 0.2 mM dithiothreitol 
and 0.1% digitonin, was mixed at the desired molar ratio with G-actin (fi- 
nal concentration 6.5 ~M) in a total volume of 60 ~L Actin polymerization 
was initiated by the addition of KCI to 1130 mM and MgCI  2 to 2 mM. After 
incubation for 1 h  at room temperature, the samples were subjected to 
centrifugation at 20,000 g for 20 min (Meyer and Aebi, 1990) followed by 
analysis of the supernatants and resuspended pellets on Coomassie blue- 
stained SDS-polyacrylamide gels. 
Measurement of Viscosity 
Viscosity measurements  were made by microcapillary falling ball viscome- 
try as described by MacLean-Fletcher and Pollard (1980b). Concentrated 
G-actin was mixed at the desired molar ratio with ot-actinin or dystrophin- 
glycoprotein complex (final actin concentration 6  p~M) in 10 mM Tris- 
HCI, pH 8.0, 1 mM NAN3, 0.1 mM ATP, 0.2 mM dithiothreitol, 0.1% digi- 
tonin, 100 mM KCI, and 2 mM MgC12, and in the absence or presence of 
9 ~M PIP2 (the kind gift of Dr. Richard Anderson, University of Wiscon- 
sin, Madison, WI). Immediately after adding actin, the samples were drawn 
into 100-pA capillary tubes (VWR Scientific, Inc., Philadelphia, PA) and 
held horizontally. After incubation for 1 h, the velocity of a 0.64-mm di- 
ameter stainless steel ball (kindly provided by Dr. Tom Pollard, Salk Insti- 
tute, La Jolla, CA) was measured at 25°C by recording the time required 
for the ball to travel 2-cm through the capillary tube inclined at 80°C. The 
viscosity values were obtained after calibration of the viscometer against 
various concentrations of glycerol (MacLean-Fletcher and Pollard, 1980b). 
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3  p~M G-actin was polymerized for 30 min at room temperature in actin 
binding buffer in the absence or presence of 0.42 mg/ml dystrophin-glyco- 
protein complex (0.5 p.M dystrophin) or 0.110 mg/ml (0.5 ~M) a-actinin. 
Samples  were  applied  to  carbon-coated  copper  grids  and  negatively 
stained with 2% uranyl acetate before examination in a Hitachi 600 elec- 
tron microscope. 
Calpain Digestion 
0.342  mg/ml dystrophin-glycoprotein complex was incubated with 0.083 
mg/ml m-calpain (Sigma) for 60 min at 25°C in actin binding buffer con- 
taining 2 mM CaCl2 instead of EGTA. Proteolysis was terminated with 
the addition of E-64 (Sigma) to a final concentration of 5 i~g/ml and the di- 
gested dystrophin-glycoprotein complex was incubated for an additional 
30 min at 25°C in the absence or presence of 6.5 ~M F-actin. After centrif- 
ugation at 100,000 g for 20 min, equal volumes of supernatants and pellets 
were electrophoretically separated on 3-12%  SDS polyacrylamide gels, 
transferred to nitrocellulose, and stained with dystropbin-specific  antibod- 
ies as previously described (Ervasti and Campbell, 1993a). 
Antibodies 
Rabbit 47 polyelonal antisera and monoclonal antibody XIXC2 were the 
kind gift of Dr. Kevin Campbell (University of Iowa, Iowa City, IA). Rab- 
bit 47  antisera were raised against a  synthetic peptide representing the 
amino-terminal 15 amino acids of human dystrophin (Ervasti et al., 1991) 
while monoclonal antibody XIXC2  (Ervasti et al., 1990)  recognizes an 
epitope located within dystrophin amino acids 1416-1494  (K. Campbell, 
personal communication). Monoclonal antibody DYS1, raised against a 
recombinant protein corresponding to dystrophin amino acids 1181-1388, 
monoclonal antibody 50DAG against adhalin/ct-sarcoglycan amino acids 
217-289 and monoclonal antibody 43DAG against the COOH-terminal 15 
amino acids of 13-dystroglycan were all purchased from Novocastra Labo- 
ratories (Newcastle, UK) through Vector Laboratories. A monoelonal an- 
tibody specific for PIPz (Fukami et at., 1992) was generously provided by 
Dr. TadaomJ Takenawa (University of Tokyo, Tokyo, Japan). The PIPz-spe- 
cific monoclonal antibody was tested for reactivity with dystrophin-glyco- 
protein complex preincubated in the absence or presence of 9 ixM PIP2 us- 
ing skeletal muscle ct-actinin as a positive control (Fukami et al., 1992). 
Recombinant Dystrophin Fragment Expression 
and Purification 
The  plasmid pRSVDy, encoding full-length dystrophin  (Acsadi  et  al., 
1991),  was the kind gift of Dr. Jon Wolff. A  DNA fragment encoding 
amino acids 1-246 of dystrophin was PCR-amplified from pRSVDy using 
the following pairs of oligonucleotide primers (Integrated DNA Technol- 
ogies, Coralville, IA): 5'-ATCACATGTTGTGGTGGGAAGAAGTA- 
GAGGACTG3', and 5'-ATCCATGGGTI'CAATGCTCACTTGTYGA- 
GGC-3'. The resulting PCR product was subcloned into the EcoRV site 
of pCR3, cut out with AfllII and NcoI, and inserted into the Ncol site of 
pET16b (Novagen, Inc., Madison, WI) to produce pDYS246. 
A  DNA fragment encoding amino acids 1416-1880 of dystrophin was 
PCR-amplified from pRSVDy and the following pair of oligonucleotide 
primers (GIBCO BRL, Gaithersburg, MD): 5'-ATCCATATGGAqT17G- 
ACAAGTCATGAGATC-3', and 5'-ATCGGATCCATACCACTGAT- 
GAGAAATYFC-3'. The PCR product was subcloned into the TA site of 
PCRII using the Original TA Cloning Kit (Invitrogen Corp., San Diego, 
CA). The insert was then cut out with NdeI and BamHI and ligated into 
pET16b previously digested with NdeI and BamHI, producing the plas- 
mid pDYS1416. 
The recombinant proteins DYS246 and DYS1416 were purified from 
cell lysates obtained after IPTG  induction of E.  coli  transformed with 
pDYS246 or pDYS1416 using the His-Bind system (Novagen) per manu- 
facturer's instructions. DYS246 or DYS1416  in elution buffer (250  mM 
imidazole, 500 mM NaC1, 20 mM Tris-HCl, pH 7.9) were dialyzed into 
50 mM Tris-HCI, pH 8.0, containing either 100 mM or 500 mM NaCl, and 
concentrated using a  Centricon-3 (Amicon). Recombinant protein con- 
centrations were determined with the Bio-Rad DC Protein Assay using 
BSA as a standard. DYS246 was confirmed by Western blot analysis with 
rabbit 47  polyclonal antisera (Ervasti et al.,  1991)  while DYS1416  was 
confirmed by Western blot analysis with monoclonal antibody XIXC2 
(Ervasti et al., 1990; Ervasti and Campbell, 1991). 
Results 
Characterization of Dystrophin--Glycoprotein Complex 
Binding to F-Actin 
As  previously  demonstrated  (Ervasti  and  Campbell, 
1993a), incubation of subrnicromolar concentrations of pu- 
rified dystrophin-glycoprotein complex with F-actin fol- 
lowed by high-speed sedimentation (100,000 g for 20 min) 
resulted in the cosedimentation of a significant amount of 
dystrophin-glycoprotein complex with the  F-actin pellet 
(Fig. 1). Even at eightfold higher concentrations, virtually 
no  (<2%)  dystrophin-glycoprotein complex sedimented 
in the absence of F-actin (Fig. 1 A). Neither dystrophin- 
glycoprotein complex nor actin sedimented at 100,000 g if 
the assay was instead performed by incubation of dystro- 
phin-glycoprotein complex with 6 IxM G-actin in the ab- 
sence of KCI and  MgCl2  (not shown).  Incubation of in- 
creasing  amounts  of  dystrophin-glycoprotein  complex 
with a fixed amount of F-actin followed by high speed sed- 
imentation demonstrated that dystrophin-glycoprotein com- 
plex bound F-actin in a saturable manner (Fig. 1 B). Non- 
linear regression analysis of the binding data from three 
independent experiments with different dystrophin-glyco- 
protein complex and actin preparations (Fig. 1 B) yielded 
an average dissociation constant (Kd) of 0.5 IxM and satu- 
ration (Brnax) at 0.042 -+ 0.005 mol/mol, which corresponds 
to one dystrophin per 24 actin monomers. The shape of 
the curve as well as the calculated Hill coefficient (1.40 _+ 
0.33) suggested that dystrophin in the glycoprotein com- 
plex bound  F-actin  with  little  or  no  cooperativity. The 
NaC1  concentration and  pH  dependence of dystrophin- 
glycoprotein complex binding to F-actin was measured at 
a dystrophin concentration of 0.5  IxM in order to detect 
whether these changes in buffer conditions altered the af- 
finity and/or maximal binding of dystrophin-glycoprotein 
complex to F-actin.  Dystrophin-glycoprotein complex co- 
sedimentation with F-actin was  independent of different 
pH conditions in the range of pH 6.5 to 8.0 but was found 
to be sensitive to increasing NaC1 concentrations ranging 
from 0.02 to 0.5 M (Fig. 2). The results presented in Figs. 1 
and 2  demonstrate  that purified skeletal  muscle  dystro- 
phin-glycoprotein  complex  binds  specifically to  F-actin 
with biochemical properties similar to other native mem- 
bers of the actin cross-linking superfamily. 
Because the effect of calmodulin on the binding of re- 
combinant dystrophin amino-terminal domain to F-actin 
has been examined by several groups yielding conflicting 
results  (Bonet-Kerrache et  al.,  1994;  Jarrett  and Foster, 
1995;  Winder  and  Kendrick-Jones,  1995),  we  further 
tested  calmodulin  for effect on  dystrophin-glycoprotein 
complex binding to F-actin. We detected no effect of 5 ~M 
bovine brain calmodulin on dystrophin-glycoprotein com- 
plex cosedimentation with F-actin when tested in the pres- 
ence of either 1 mM EGTA or 0.2 mM CaCI2 (Fig. 2). The 
bovine brain calmodulin was determined to be functional 
by its calcium-dependent binding to purified calcium/calmod- 
ulin kinase II (Ervasti and Campbell, 1993a)  as well as its 
ability to stimulate myosin light chain kinase activity with 
corresponding effects on myoflbrillar contraction (J.R. Pa- 
tel and R.L. Moss, personal communication). 5 ixM calmod- 
ulin purified from wheat germ also had no effect on dys- 
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Figure 2.  Effect of NaC1, pH, calcium and calmodulin on dystro- 
phin-glycoprotein  complex cosedimentation with F-actin. High- 
speed cosedimentation assays were performed in the presence of 
6.5 ~M F-actin and 0.43 mg/ml dystrophin-glycoprotein complex 
(0.5 ~M dystrophin). The binding data were normalized against 
the amount of actin pelleted and expressed as percent of the dys- 
trophin-glycoprotein  complex pelleted  with F-actin under  con- 
trol conditions (0.1 M NaCI, 1 mM EGTA, pH 8.0) where 100% 
equals 0.019 -_+ 0.002 mol dystrophin bound per mol actin. The ef- 
fect of 0.2 mM CaCI2  was examined in the absence of EGTA. The 
concentration of calmodulin (CAM) was 0.08 mg/ml (5 I~M). 
Figure 1.  Cosedimentation  of the dystrophin-glycoprotein  com- 
plex with F-actin. Shown in A are Coomassie blue-stained  SDS- 
polyacrylamide gels of 100,000 g supernatants (S) and pellets (P) 
of dystrophin-glycoprotein  complex incubated  in the  presence 
(DGC +  ACT) or absence (DGC) of F-actin, or F-actin alone 
(ACT). The  concentration  of dystrophin-glycoprotein complex 
was 0.21 mg/ml (0.25 txM dystrophin) in (DGC + ACT) and 1.83 
mg/ml (2.14 p~M dystrophin) in DGC; F-actin was present at 6 I~M 
in all panels. The molecular weight standards (x  10  -3) are indi- 
cated on the left. (B) Increasing amounts of dystrophin-glycopro- 
tein  complex were  incubated  with 6.5  I~M F-actin with subse- 
quent centrifugation at 100,000 g. The amount of free and bound 
dystrophin  was  determined  densitometrically  from  Coomassie 
blue-stained  gels of 100,000 g supernatant  and pellet fractions as 
shown in A. The binding data were fitted using nonlinear regres- 
sion analysis. Different  symbols denote  the data  of three  inde- 
pendent experiments performed with different dystrophin-glyco- 
protein complex and F-actin preparations. 
trophin-glycoprotein  complex  binding  to  F-actin  (not 
shown). 
Failure of Dystrophin-Glycoprotein Complex 
to Cross-link F-Actin 
Dystrophin is commonly modeled as an antiparallel dimer 
based primarily on its  sequence homology with  spectrin 
(Koenig et al., 1988). If dystrophin exists as a dimer in the 
glycoprotein complex it would be  expected to cross-link 
actin filaments into supermolecular networks or bundles. 
To test this hypothesis, G-actin was polymerized to F-actin 
in the absence or presence of dystrophin-glycoprotein com- 
plex or a-actinin, then negatively stained with uranyl ace- 
tate and examined by electron microscopy (Fig. 3). F-actin 
bundles were  readily apparent  when actin was polymer- 
ized in the presence of et-actinin  at a ratio of one a-actinin 
per  six  actin  monomers.  However,  no  F-actin  bundles 
were observed when actin was polymerized alone or in the 
presence of dystrophin-glycoprotein complex at ratios as 
high as one dystrophin per six actin monomers. 
The failure of dystrophin-glycoprotein complex to bun- 
dle F-actin (Fig. 3) did not rule out the possibility that dys- 
trophin may cross-link actin filaments into loose networks 
that were not discernible by electron microscopy. There- 
fore, low speed sedimentation analysis of dystrophin-gly- 
coprotein complex/F-actin mixtures was performed. It has 
been previously shown (Meyer and Aebi, 1990) that F-actin 
does not sediment under low speed (20,000 g) centrifuga- 
tion conditions unless complexed into supermolecular ag- 
gregates by a cross-linking protein such as a-actinin (Fig. 4 A). 
The presence of both F-actin and dystrophin-glycoprotein 
complex in the supernatant fraction after centrifugation at 
20,000 g (Fig.  4 B) indicated that dystrophin-glycoprotein 
complex did not cross-link F-actin. Dystrophin-glycopro- 
tein complex was unable to effect the low speed sedimen- 
tation of F-actin even at a dystrophin/actin molar ratio as 
high as 1:4 (not shown). High speed sedimentation analy- 
sis performed in parallel  with  the low speed experiment 
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lymerized in the absence or presence of dystrophin-glycoprotein 
complex or ~t-actinin. 3 txM G-actin was polymerized alone or in 
the  presence of dystrophin-glycoprotein complex or ct-actinin, 
the samples stained with uranyl acetate and visualized by electron 
microscopy.  The dystrophin/F-actin  and e~-actinin/F-actin molar 
ratio was 1:6. Bar, 200 nm. 
(Fig. 4 B) confirmed that G-actin had polymerized to F-actin 
and that dystrophin-glycoprotein complex bound F-actin. 
The inability of dystrophin-glycoprotein complex to cosedi- 
ment with F-actin at low speed was not the result of pro- 
teolytic cleavage of the amino-terminal domain of dystro- 
phin, as an antibody specific for the first 15 amino acids of 
dystrophin (Ervasti et al., 1991)  strongly reacted on West- 
ern blots containing the 20,000 g supernatant (not shown). 
Furthermore, neither 0.2 mM CaCI2 nor 5 IzM calmodulin 
induced  dystrophin-glycoprotein  complex  to  cross-link 
F-actin as assessed by the low speed sedimentation assay 
(not shown). 
Since  F-actin  cross-linked  by  dystrophin-glycoprotein 
complex may be so rigid that it is not sedimented at low 
speed  (Pollard  and  Cooper,  1982),  the  effect of dystro- 
phin-glycoprotein  complex on  gelation  of actin-filament 
solutions was examined by falling-ball viscometry, ct-Acti- 
nin increased  the  viscosity of F-actin more than  2.5-fold 
when present at a 1:20 molar ratio with F-actin and formed 
a  gel when et-actinin and actin were mixed at a  1:5 molar 
ratio (Fig. 5). In contrast with a-actinin, dystrophin-glyco- 
protein complex had no effect on the gelation of F-actin as 
the viscosity of F-actin did not change in the presence of 
dystrophin-glycoprotein complex (Fig. 5)  at molar ratios 
Figure 4.  Low speed sedimentation analysis of F-actin cross-link- 
ing by et-actinin and dystrophin-glycoprotein  complex. Shown in 
A  is  the  Coomassie blue-stained  SDS-polyacrylamide gel  of 
20,000 g supernatants  (S) and pellets (P) of F-actin incubated in the 
absence or presence of ct-actinin. The concentration of ct-actinin 
was 0.2 mg/ml (1 izM); F-actin was present at 5 IzM. Shown in B 
are  the  Coomassie  blue-stained  SDS-polyacrylamide gels  of 
20,000 g and 100,000 g supernatants (S) and pellets (P) of F-actin 
incubated in the presence or absence of dystrophin-glycoprotein 
complex. The concentration of dystrophin-glycoprotein complex 
was 0.42 mg/ml (0.5 ixM dystrophin); F-actin was present at 6.5 IxM. 
The molecular weight standards (× 10  -3) are indicated on the left. 
as high as 1:5. Whereas the dystrophin-glycoprotein com- 
plex remains intact during membrane solubilization in 1% 
digitonin and 0.5 M NaCI (Ervasti et al., 1990; Yoshida and 
Ozawa,  1990;  Ervasti  and  Campbell,  1991;  Ervasti  et  al., 
1991),  it  is  possible  that  these  solubilization  conditions 
may specifically dissociate dystrophin dimers or alter the 
complex in some other manner such that it is incapable of 
crosslinking  F-actin.  To  address  this  possibility,  dystro- 
phin-glycoprotein  complex  was  solubilized  from  mem- 
branes with 1% Triton X-100 and 0.15  M  NaCI and chro- 
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Figure 5.  Effect of t~-actinin and dystrophin-glycoprotein  com- 
plex on the viscosity of F-actin. Average viscosity measurements 
(_+ SEM, n 1> 3) obtained  by falling ball viscometry at 25°C are 
expressed as the percent of that obtained for 6 ~M F-actin alone 
(60.37 -+ 2.01 cP). Gel indicates a viscosity at which the ball does 
not fall. The concentrations of c~-actinin were 0.06 mg/ml (0.3 ~M) 
and 0.24 mg/ml (1.2 p,M). Dystrophin-glycoprotein  complex was 
present at concentrations 0.26 mg/ml and 1 mg/ml (0.3 IxM and 
1.2 ~M dystrophin, respectively). F-actin was present at 6 ~xM in 
all assays. The cross-hatched bars illustrate data obtained in the 
presence of 9 txM PIP  2. 
rnatographically purified in the presence of 0.1%  Triton 
X-100 instead of digitonin. Whereas the complex purified 
from low salt Triton X-100 solubilates cosedimented spe- 
cifically with F-actin in the high speed assay, it also failed 
to cross-link F-actin as assessed in the low speed sedimen- 
tation assay and by falling-ball viscometry (not shown). It 
is also possible that association with the glycoprotein com- 
plex prevents dystrophin from cross-linking F-actin. How- 
ever, dystrophin dissociated from the  glycoprotein com- 
plex by treatment with  13-octylglucoside  (Yoshida  et al., 
1994) also exhibited no measureable F-actin cross-linking 
activity (not shown). These results suggest that the failure 
of dystrophin-glycoprotein complex to cross-link F-actin 
was not due to an adverse affect of its purification or inter- 
action with associated proteins. 
As PIP2 has been shown to inhibit the actin binding ac- 
tivity of dystrophin purified from Torpedo electric organ 
(Mejean et al.,  1995), it remained possible that the failure 
of dystrophin-glycoprotein complex to cross-link F-actin 
might be due to presence of copurifying polyphosphoino- 
sitides. However, purified dystrophin-glycoprotein complex 
failed to react with PIP2-specific antibodies (Fukami et al., 
1992)  while the presence of 9  ~LM PIP2 or pretreatment 
with phosphatidylinositol-specific phospholipase C had no 
effect on dystrophin-glycoprotein  complex binding to F-actin 
as assessed in the high-speed and low-speed sedimentation 
assays (not shown). Furthermore, 9 t~M PIP2 had no effect 
on the gelation of F-actin in the presence of dystrophin- 
glycoprotein complex even though the same concentration 
of PIP2 dramatically stimulated the F-actin gelating activ- 
ity of smooth muscle ct-actinin (Fig.  5).  Taken together, 
the results presented in Figs. 3-5 demonstrate that purified 
dystrophin-glycoprotein complex is  unable  to  cross-link 
actin filaments into supermolecular networks or bundles. 
Evidence for a Novel F-Actin Binding Site 
in Dystrophin 
In the initial study that identified the region of dystrophin 
responsible  for interaction  with  the  glycoprotein com- 
plex (Suzuki et al., 1992), it was shown that limited calpain 
digestion  of  purified  dystrophin-glycoprotein  complex 
yielded a stable series of dystrophin fragments while inte- 
gral membrane components of the glycoprotein complex 
were not digested.  Identification of calpain-derived dys- 
trophin  fragments  with  sequence-specific antibodies  re- 
vealed a stable 31 kD fragment that corresponded to the 
amino-terminal, putative actin-binding domain of dystro- 
phin  (Suzuki  et  al.,  1992).  Using  a  similar  strategy, we 
sought to identify dystrophin fragments that cosedimented 
with F-actin after limited calpain digestion of dystrophin- 
glycoprotein complex. Surprisingly, the 31 kD dystrophin 
fragment recognized by antibodies specific for the amino- 
terminal 15 amino acids of dystrophin did not cosediment 
with F-actin when 0.4  txM of digested dystrophin-glyco- 
protein complex was analyzed in the high speed sedimen- 
tation  assay  (Fig.  6).  However, dystrophin monoclonal 
antibody XIXC2 (Ervasti et al., 1990), which maps to an 
epitope  contained  in  dystrophin  amino  acids  1416-1494 
(Campbell,  K., personal communication) did identify a 
50  kD  fragment  of the  dystrophin rod  domain  that  re- 
tained F-actin binding activity (Fig. 6). The 50 kD, actin 
binding  fragment  of  dystrophin  was  further  localized 
within the rod domain by the absence of reactivity with 
Figure 6.  Cosedimentation  of dystrophin fragments with F-actin 
after limited digestion of dystrophin-glycoprotein  complex with 
calpain. Shown are identical nitrocellulose transfers stained with 
rabbit  polyclonal  antibodies  raised  against  a  synthetic  peptide 
corresponding to the first 15 amino acids of dystrophin (Rb 47), 
or monoclonal antibodies XIXC2 and DYS1 that are specific for 
adjacent  (but not overlapping)  epitopes  located  in the rod do- 
main of dystrophin (refer to Fig. 7). The nitrocellulose transfers 
contained electrophoretically separated supernatants  (S) and pel- 
lets (P) of calpain-digested dystrophin-glycoprotein  complex in- 
cubated in the presence (+ F-actin)  or absence (- F-actin) of 
F-actin and sedimented at 100,000  g. The arrows identify the 31-kD 
and  50-kD  dystrophin  fragments  detected  by  rabbit  47  and 
XIXC2 antibodies,  respectively.  The concentration of calpain- 
digested dystrophin-glycoprotein complex was 0.34 mg/ml (0.4 I~M 
dystrophin)  and F-actin was present at 6.5 ~M. The molecular 
weight standards (× 10  -3) are indicated on the left. 
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epitope located within dystrophin amino acids 1030-1388 
(Nicholson et al., 1989). Nitrocellulose transfers stained with 
monoclonal  antibodies  specific for adhalin/et-sarcoglycan 
and 13-dystroglycan indicated that neither of these integral 
membrane  components  of  the  dystrophin-glycoprotein 
complex was digested by m-calpain or cosedimented with 
F-actin after calpain digestion of the dystrophin-glycopro- 
tein complex (not shown). These results suggest that a por- 
tion of the dystrophin rod domain may also play a role in 
the actin binding activity of dystrophin. 
In order to confirm the actin binding activity of the 50-kD 
fragment of the dystrophin rod domain (Fig. 6), recombi- 
nant proteins corresponding to dystrophin amino acids 
1-246  (DYS246)  and  1416-1880  (DYS1416)  were  evalu- 
ated  for  interaction  with  F-actin  using  the  high  speed 
sedimentation assay. Both recombinant proteins were ob- 
served to specifically cosediment with F-actin (Fig. 7 A). 
Neither 5 IxM calmodulin or 9 IxM PIP2 had any effect on 
the cosedimentation of DYS246 with F-actin (not shown). 
It was not possible to  accurately measure the  affinity or 
stoichiometry of either protein for F-actin because higher 
but  subsaturating  protein  concentrations  sedimented  in 
the absence of F-actin. However, it was apparent from the 
binding data obtained over the measurable concentration 
range that DYS246 and DYS1416 both bound F-actin with 
substantially lower affinity and higher capacity (Fig. 7 B) 
than was observed with purified dystrophin-glycoprotein 
complex (Fig.  1).  These  results could  be explained  by a 
model whereby intact dystrophin binds with 0.5 IxM affin- 
ity  to  F-actin  through  the  combined  effect  of multiple 
lower affinity contact sites. 
Effect of Dystrophin-Glycoprotein Complex 
on F-Actin Depolymerization 
The  stoichiometry  of  dystrophin-glycoprotein  complex 
binding to F-actin (1  dystrophin per 24 actin monomers, 
Fig. 1), the lack of cross-linking activity (Figs. 3-5) and the 
evidence for an additional actin binding site located in the 
rod domain (Figs. 6  and 7) raise the possibility that full- 
length  dystrophin  may  bind  along  an  actin  filament 
through  interaction  with  multiple  actin  monomers  in  a 
manner analogous to side-binding proteins like tropomyo- 
sin (Broschat, 1990).  If dystrophin indeed binds along an 
actin filament, it might further be expected to prevent or 
retard the dissociation of actin monomers from the ends of 
filaments to which it is bound (Broschat, 1990; Schafer and 
Cooper, 1995). To test this hypothesis, F-actin alone, or 
F-actin  pre-equilibrated  with  dystrophin-glycoprotein 
complex was rapidly diluted into buffer conditions that fa- 
vored actin depolymerization. At various times post-dilu- 
tion, the amount of F-actin remaining was determined by 
Figure 7.  Cosedimentation of recombinant dystrophin  fragments 
with F-actin. Shown in A is a diagram illustrating  the location of 
epitopes for Rb 47 (amino acids 1-15), XIXC2 (amino acids 1416- 
1494) and DYS1 (amino acids 1181-1388) in the dystrophin pri- 
mary sequence as well as the relative location  of the dystrophin 
sequences  encoded by recombinant proteins DYS246 (amino ac- 
ids 1-246) and DYS1416 (amino acids 1416-1880). Also shown in 
A  are Coomassie blue-stained SDS-polyacrylamide gels of su- 
pernatants  (S)  and  pellets  (P)  of  recombinant  DYS246  and 
DYS1416 sedimented at 100,000 g in the presence or absence of 
F-actin. (B) Increasing amounts of DYS246 or DYS1416 were in- 
cubated with 6.5  I~M F-actin  with  subsequent centrifugation  at 
100,000 g. The amount of free and bound protein was determined 
densitometrically  from Coomassie blue-stained  gels of 100,000 g 
supernatant and pellet fractions as shown in A. 
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sized,  preequilibration  of dystrophin-glycoprotein com- 
plex with F-actin significantly slowed the  depolymeriza- 
tion of F-actin when compared to F-actin alone (Fig. 8). 
For example,  4  h  after dilution,  4.6  +_  1.9%  of F-actin 
alone pelleted while 14.9 __+ 0.2% pelleted when dystrophin- 
glycoprotein complex was present at a 1:5 molar ratio with 
F-actin. We further determined the molar ratio of dystro- 
phin that cosedimented with actin using the densitometri- 
cally determined fraction of each protein that  pelleted 
and the total protein concentrations. Over the time range 
of 50-80  min  post-dilution,  the  average  molar ratio  of 
dystrophin  that  cosedimented with  the  actin  pellet was 
0.13  _  0.02.  Preliminary fluorescence experiments using 
pyrene-labeled actin (Cooper et al., 1983) confirmed that 
dystrophin-gtycoprotein  complex significantly slowed F-actin 
depolymerization but had no effect on F-actin polymeriza- 
tion (not shown). While it is possible that the protective 
effect of dystrophin-glycoprotein complex on actin depoly- 
merization is a general feature of proteins that bind F-actin 
(Schafer and  Cooper, 1995), et-actinin only slowed actin 
depolymerization at the earliest measurable time point (20 
rain) while the protective effect of dystrophin-gtycopro- 
tein complex persisted for at least 4 h post-dilution (Fig. 8). 
These data, together with the stoichiometry of dystrophin- 
glycoprotein complex binding to F-actin (Fig. 1), suggest 
that an intact dystrophin molecule has the capacity to in- 
teract directly with multiple actin monomers within a fila- 
ment. 
Discussion 
Although dystrophin is clearly an essential muscle protein, 
little is known about its physiological role(s) in maintain- 
ing cellular viability. The functional importance of the cys- 
teine-rich and carboxy-terminal domains of dystrophin is 
evident from several studies that correlate specific muta- 
tions or deletions in these domains with presentation of 
the most severe forms of muscular dystrophy (Hoffman 
et al., 1991; Helliwell et al., 1992; Matsumura et al., 1993). 
Localization of the binding sites for dystrophin-associated 
proteins  to  the  cysteine-rich  and  carboxy-terminal  do- 
mains (Suzuki et al., 1992; Kramarcy et al., 1994; Suzuki et 
al., 1994) demonstrated that these two domains are essen- 
tial for normal dystrophin function in skeletal muscle. On 
the other hand, transgenic expression of a nonmuscle iso- 
form  of dystrophin  (DP71)  lacking  the  amino-terminal 
and rod domains in dystrophin-deficient muscle leads to 
the restoration of dystrophin-associated proteins but fails 
to  correct  the  dystrophic phenotype  (Cox  et  al.,  1994; 
Greenberg et al.,  1994).  These data indicate that the cys- 
teine-rich  and  carboxy-terminal  domains  of  dystrophin 
alone  are  insufficient to  confer normal  muscle  function 
and leave unresolved the functional role of the remaining 
80% of dystrophin sequence comprising the amino-termi- 
nal and rod-like domains. 
Certainly, the strong sequence homology of the amino- 
terminal  246  amino  acids  of dystrophin  with  the  actin 
binding  domains  of  several  well-characterized  F-actin 
cross-linking  proteins  (Koenig  et  al.,  1988;  Matsudaira, 
1991) and accumulating data (Hemmings et al., 1992; Way 
et al., 1992; Fabbrizio et al., 1993; Corrado et al., 1994; Jar- 
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Figure 8.  Effect of dystrophin-glycoprotein complex and et-actinin 
on the depolymerization of F-actin. 7.5 ~M F-actin in G-buffer con- 
taining 10 mM NaCI and 0.2 mM MgC12 was incubated 30 min at 
room temperature alone (circles)  or in the presence of dystrophin- 
glycoprotein complex (inverted  triangles)  or a-actinin  (squares), 
both present at a 1:5 molar ratio with respect to actin. The sam- 
ples were rapidly diluted threefold into G-buffer and centrifuged 
at 100,000 g for 20 min after various incubation times post-dilu- 
tion. The fraction of actin (% F-actin) remaining in the pellet was 
determined densitometrically from Coomassie blue-stained gels 
loaded with equal volumes of supernatants  and pellets. The up- 
per panel shows the entire time range evaluated while time points 
between 0 and 80 min are shown in expanded form in the lower 
panel. Time points include centrifugation time and represent the 
average (_+ SEM) of three or more independent determinations. 
rett  and  Foster,  1995)  support  its  hypothesized role  in 
binding F-actin. In addition, several studies have noted a 
correlation between mutations or deletions in the amino- 
terminal domain with the expression of intermediate to se- 
vere forms of muscular dystrophy (Beggs et al., 1991; Prior 
et al., 1993; Winnard et al., 1993; Comi et al., 1994; Mun- 
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severe phenotypes presented by'patients: with defects or 
deletions in the amino-terminal domain are due to the ab- 
sence of an important functional domain or simply to the 
low abundance of an unstable truncated protein. In fact, 
transgenic mdx mice expressing normal levels of a dystro- 
phin construct lacking amino acids 45-273 present with a 
benign phenotype, indicating that the amino-terminal do- 
main is not essential for normal dystrophin function (Cor- 
rado et al., 1996).  In this study, we present evidence sug- 
gesting that both the amino-terminal and rod domains of 
dystrophin are involved in binding to actin filaments. 
Dystrophin in the glycoprotein complex bound F-actin 
in a specific and saturable manner with an average Kd of 
0.5 I~M (Fig. 1). Other studies have estimated 0.1-1.0 IxM 
F-actin binding affinities for purified Torpedo dystrophin 
(Lebart et al.,  1995)  as well as maltose binding protein/ 
dystrophin chimeras comprising the first 90 to 385 amino 
acids of dystrophin (Corrado et al., 1994; Jarrett and Fos- 
ter, 1995). These results could be taken to suggest that the 
amino-terminal domain of dystrophin is  sufficient to ac- 
count for the actin binding activity of dystrophin. How- 
ever,  binding  constants  were  estimated  using  a  direct 
ELISA assay which,  for a  variety of reasons (Goldberg 
and Djavadi-Ohaniance, 1993), is generally considered in- 
appropriate for measuring ligand binding affinity. Further- 
more, it is unclear what conformational effect the >40 kD 
maltose binding protein portion of the chimeras may have 
exerted on the normally unconstrained amino terminus of 
native  dystrophin. We expressed a  recombinant protein 
initiated at the start methionine of dystrophin (DYS246). 
DYS246 comprises the amino-terminal 246 amino acids of 
dystrophin with a small (N5 kD), carboxy-terminal poly- 
histidine tag which facilitated rapid purification to >95% 
purity. Although saturation was not measurable, DYS246 
clearly bound F-actin in the high-speed sedimentation as- 
say with at least an order of magnitude lower affinity and 
substantially higher capacity (Fig. 7) than was observed for 
purified dystrophin-glycoprotein complex (Kd  =  0.5  IxM, 
Bmax =  1:24, Fig. 1). Consistent with our results, it was pre- 
viously demonstrated (Way et al., 1992) that a non-fusion 
recombinant protein corresponding to dystrophin amino 
acids 1-246  bound F-actin with 1:1 stoichiometry and an 
apparent K d of 44 IxM when measured in the high-speed 
sedimentation assay.  Taken together, these  data suggest 
that the amino-terminal, putative actin binding domain of 
dystrophin alone is insufficient to explain the F-actin bind- 
ing properties of full-length dystrophin. 
Regarding regulation of dystrophin binding to F-actin, 
we observed no effect of either calmodulin or PIP2 as re- 
ported by others (Jarrett and Foster, 1995; Mejean et al., 
1995).  The reason for these different results is  not pres- 
ently clear. In the case of PIP2, our conflicting results may 
reflect a difference in sequence between mammalian skel- 
etal muscle dystrophin and Torpedo electric organ dystro- 
phin that confers sensitivity to PIP2.  While the complete 
amino acid sequence for Torpedo dystrophin has not been 
determined, the PIP2 binding site in the actin binding do- 
main of a-actinin (Fukami et al., 1996) is poorly conserved 
with  the  analogous  sequence  in  skeletal  muscle  dystro- 
phin. With regard to calmodulin, we and others (Bonet- 
Kerrache et al., 1994; Winder and Kendrick-Jones, 1995) 
havenotb~  a~l~ to eonfirm an effect of calmodulin on 
recombinant dystrophin amino-terminal domain  binding 
to F-actin using a solution phase assay. In the study report- 
ing an effect of calmodulin (Jarrett and Foster, 1995), a di- 
rect ELISA assay was  used to show that fusion protein 
binding to immobilized actin was  fourfold higher in the 
presence of calcium than in the presence of EGTA and 
that addition of 5 ixM calmodulin reduced apparent fusion 
protein binding in the presence of calcium towards the val- 
ues obtained in EGTA. In the absence of additional con- 
trol experiments, it is possible that the observed calmodu- 
lin inhibition of fusion protein binding to actin was due to 
calcium buffering by calmodulin that may have affected 
the solubility of fusion protein or the colorimetric reaction 
used for detection. Resolution of this controversy awaits 
demonstration of a calmodulin effect on intact dystrophin 
binding to F-actin. 
Three additional experimental findings suggest that dys- 
trophin interacts with F-actin in a  manner that dramati- 
cally distinguishes it from the other proteins that comprise 
the  actin  cross-linking  superfamily  (Matsudaira,  1991). 
First, dystrophin is commonly modeled as an antiparallel 
dimer based primarily by analogy to a-actinin and spectrin 
(Koenig et al., 1988; Matsudaira,  1991)  and would there- 
fore be expected to cross-link actin filaments into super- 
molecular networks or bundles.  However, dystrophin in 
the glycoprotein complex was unable to cross-link F-actin 
when examined by three different methods, all carried out 
in parallel with a-actinin as a positive control (Figs. 3-5). 
While recombinant proteins corresponding to dystrophin 
repeats two and three of the rod domain have a conforma- 
tion  similar  to  that  of spectrin  repeats  (Kahana  et  al., 
1994),  it has  been  cautioned that  conservation between 
dystrophin repeats is much lower than in the case of spec- 
trin (Tinsley et al.,  1992), particularly with regard to sur- 
face  residues  thought  to  be  important  in  dimerization 
(Winder et al.,  1995). Images obtained from rotary-shad- 
owed dystrophin preparations (Pons et al., 1990) revealed 
the presence of dystrophin monomers and dimers as well 
as higher ordered oligomers. As noted by the authors of 
this study (Ports et al., 1990), however, the purification of 
dystrophin involved an acid elution step from an affinity 
column which may have had some effect on the structures 
observed. While gel permeation chromatography (Yoshida 
and  Ozawa,  1990)  of  purified  dystrophin-glycoprotein 
complex yielded a molecular weight estimate (>1,000,000) 
suggestive of dimeric complex, the method relies on the 
assumption that the protein under investigation is globu- 
lar, which is probably not valid in the case of dystrophin. 
The second novel finding of this study was the identifi- 
cation of an additional F-actin binding site located near 
the middle of the dystrophin rod domain and separated 
from the amino-terminal, putative actin binding domain of 
dystrophin by almost  1,200  amino  acids  (Figs. 6  and 7). 
While remarkable, this finding is not unprecedented. For 
example,  the  first a-helical repeat of 13-spectrin  was  re- 
cently shown to participate in the binding of its amino-ter- 
minal domain to F-actin (Li and Bennett, 1996). Tensin 
exhibits homology to the consensus site found in the F-actin 
cross-linking superfamily of proteins (Matsudaira,  1991), 
yet nonhomologous sequences were shown to be respOnsi- 
ble for its actin binding activity (Lo et al.,  1994). Further- 
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its actin binding activity shows weak homology with the 
triple helical repeats common to dystrophin, et-actinin and 
spectrin (Van Etten et al., 1994). Interestingly, the portion 
of the dystrophin rod domain that exhibits actin binding 
activity (amino acids 1416-1880,  Fig. 7) also contains re- 
peats 10 and 14, which are noted for conforming poorly 
with the stereotypical repeat pattern (Koenig and! Kunkel, 
1990; Winder et al., 1995). As with the amino-terminal, pu- 
tative actin binding domain of dystrophin, a recombinant 
protein  corresponding  to  dystrophin amino  acids  1416- 
1880 appeared to bind F-actin with substantially lower af- 
finity and higher capacity (Fig. 7) than was observed for 
intact  dystrophin in  the  glycoprotein complex  (Fig.  1). 
These data support the possibility that multiple lower af- 
finity sites distributed throughout the dystrophin amino- 
terminal and rod domains may act in concert to bind dystro- 
phin to F-actin with 0.5 ~M affinity. It may be relevant that 
one study of different dystrophin fusion proteins noted ac- 
tin binding activity for a construct encoding the most distal 
repeats of the dystrophin rod domain (Jarrett and Foster, 
1995). 
As a third distinguishing feature of dystrophin binding 
to F-actin, we observed that dystrophin-glycoprotein com- 
plex significantly protected  a  fraction of actin filaments 
from depolymerization (Fig. 8).  It is noteworthy that the 
actin side-binding protein  tropomyosin binds  to  F-actin 
with a stoichiometry of one tropomyosin per seven actin 
monomers and also protects F-actin from depolymerization 
(Broschat, 1990).  On the other hand, it has been argued 
that bivalent actin binding proteins should also retard F-actin 
depolymerization as a consequence of cross-linking activ- 
ity (Schafer and Cooper, 1995). Consistent with a previous 
study (Cano et al., 1992), we observed that et-actinin signif- 
icantly stabilized F-actin for brief periods (<30 min) after 
initiation of depolymerization (Fig. 8). However, a-actinin 
failed to protect F-actin for longer time periods while dys- 
trophin-glycoprotein  complex  inhibited  F-actin  depoly- 
merization for as long as 4 h (Fig. 8). We hypothesize that 
the early protection of F-actin from depolymerization by 
et-actinin is due to the presence of bundles which rapidly 
dissociate upon dilution (Meyer and Aebi,  1990).  Since 
dystrophin-glycoprotein complex does not have  the  ca- 
pacity to cross-link actin filaments (Figs. 3-5), the more 
prolonged  protective  effect  of  dystrophin-glycoprotein 
complex on F-actin depolymerization (Fig. 8) is best ex- 
plained by a side binding interaction between dystrophin 
and F-actin.  Interestingly, although dystrophin is  highly 
susceptible  to proteolysis in  vitro  (Koenig and  Kunkel, 
1990; Suzuki et al., 1992), the amino-terminal half of the 
molecule appears to be protected from proteolysis in situ 
(Hori et al., 1995),  perhaps through a  lateral association 
with F-actin. 
In light of these results, we propose  a model in which 
the amino-terminal and rod domains both participate in 
dystrophin binding along an  actin filament through  the 
concerted effect of multiple low affinity binding sites. An 
actin side binding function for dystrophin may be particu- 
larly important for stabilizing lateral associations between 
thin filaments and the sarcolemma at myotendinous junc- 
tions  (Tidball  and  Law,  1991).  In  addition,  dystrophin 
could play a  structural role at costameres (Porter  et al., 
1992)  through a  side binding interaction with peripheral 
actin filaments emanating from the Z- and M-lines of myo- 
fibers (Bard and Franzini-Armstrong, 1991). Both of these 
specialized sites of force transmission are disrupted in dys- 
trophin-deficient mdx  mouse muscle  (Tidball  and  Law, 
1991;  Ridge  et  al.,  1994).  The  redundancy provided  by 
multiple actin binding sites may also help to explain why 
restoration of a truncated dystrophin comprising only the 
cysteine-rich and carboxy-terminal domains is insufficient 
to correct the pathologies observed in dystrophic muscle 
(Cox et al., 1994; Greenberg et al., 1994), yet no specific 
sequences within the amino-terminal (Corrado et al., 1996) 
and rod domains (England et al., 1990) also appear to be 
essential for normal dystrophin function. Perhaps  some 
mild forms of muscular dystrophy are due to gene dele- 
tions that allow the expression of sufficient portions of the 
amino-terminal and/or rod domains (in any combination 
with cysteine-rich and carboxy-terminal domains) to con- 
serve at least partial actin binding activity. The presence of 
actin binding sites within the rod domain of dystrophin 
would also provide a basis by which dystrophin isoforms 
lacking the amino-terminal domain (D'Souza et al., 1995) 
may still function in a manner analogous to full-length dys- 
trophin. 
Based on the stoichiometry of dystrophin-glycoprotein 
complex binding to F-actin (Fig. 1), a dystrophin molecule 
has the capacity to interact with 24 actin monomers which 
should span  a  length of 130  nm if arranged in a  single 
strand of a filament or one-half of this length when com- 
prising  both  strands  of  the  filament.  Either  possibility 
would be sufficient to allow linear contact with amino ac- 
ids 1-246 and 1416-1880 of an extended dystrophin mole- 
cule with a length of 120-140 nm (Cullen et al., 1990; Pons 
et al., 1990). Further refinement of the model will require 
unambiguous resolution of the oligomeric state of native 
dystrophin. Toward  this end,  experiments  are  currently 
underway to  accurately determine the  native  molecular 
weight of dystrophin-glycoprotein complex and purified 
dystrophin. 
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